Multi-center Phase 2 Study to Assess the Safety, Tolerability and Early Signs of Efficacy of Tid Orally Administered BAY63-2521 in Adult Delta F508 Homozygous Cystic Fibrosis Patients
Phase of Trial: Phase II
Latest Information Update: 09 Nov 2017
At a glance
- Drugs Riociguat (Primary)
- Indications Cystic fibrosis
- Focus Therapeutic Use
- Sponsors Bayer
- 25 Sep 2017 Planned End Date changed from 31 Jan 2018 to 2 Mar 2018.
- 25 Sep 2017 Status changed from recruiting to discontinued.
- 10 Sep 2017 This trial has been completed in Belgium (End date: 2017-08-31), as per European Clinical Trials Database record.